5 hrs ago | Motley Fool
IA could write this article the usual way -- byA showing you how to turn your thousands into millionsA through investments in solid, well-known companies.
Wesely-Thomas Enterprises weathering its second recession just fine
Wesely-Thomas Enterprises CEO Carl Wesely takes a look around an operating room at Los Robles Hospital & Medical Center in Thousand Oaks on Friday.
Amgen's Vectibix Misses Mark, But Data Inspire Some Optimism
Although Amgen Inc.'s Phase III Vectibix-Folfox combination met its main goal - to improve progression-free survival in patients with advanced colorectal cancer in the first-line setting - it missed its secondary endpoint of overall survival, the company reported Thursday.
Amgen Announces Overall Survival Results for Vectibix in First-Line Metastatic Colorectal Cancer
Amgen today announced that the Phase 3 PRIME "203" trial evaluating Vectibix administered in combination with FOLFOX as a first-line treatment of metastatic colorectal cancer failed to meet a secondary endpoint of overall survival.
Amylin signs obesity drug deal with Takeda
Amylin Pharmaceuticals Inc. says it could potentially receive more than $1 billion from a partnership with Japan's Takeda Pharmaceutical Co.
Hawaii participates in fraud case against drug maker Amgen
Hawaii is one of several states suing biotechnology behemoth Amgen Inc. for allegedly giving kickbacks to medical providers to help boost sales of the anemia drug Aranesp.
Indiana, other states sue biotech firm Amgen
Amgen Inc., the world's largest biotechnology company, is being sued by Indiana, New York and 13 other states following an investigation into a national kickback scheme to boost drug sales, New York Attorney General Andrew Cuomo said.
Customer Interaction Solutions
Stock-PR.com Announces Daily Stock Watch: NVAX, HGSI, AMGN
Stock-PR.com, a division of Crown Equity Holdings Inc. tracks stocks daily and is pleased to offer its hot stock alerts.
State AGs Suing U.S. Drug Maker Amgen
Several state attorneys general allege the U.S. biotechnology firm Amgen Inc. has engaged in illegal kickbacks to help sales of its anemia drug Aranesp.
Los Angeles Business Journal Online -...
Amgen Sued Over Alleged Kickbacks
Amgen Inc. on Friday was sued by 14 states and the District of Columbia, which accuse the Thousand Oaks biotech of offering kickbacks to medical providers to boost sales of its troubled anemia drug Aranesp.
Large Study of Anemia Treatment in Chronic Kidney Disease Patients...
Amgen today announced the publication of results from TREAT , a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease not on dialysis, moderate anemia and type-2 diabetes.
Study finds stroke risk from anemia drug Aranesp
A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick enough to need dialysis.
15 States Sue Amgen Alleging Kickback Scheme
Biotechnology behemoth Amgen Inc. is being sued by 15 states alleging a scheme of kickbacks to medical providers to help boost sales of the anemia drug Aranesp.
Watching insiders is like participating in a weeks-long stakeout. You expect something to happen, but you don't know what.
Market Winners & Losers: New York Times, Janus Capital
The major indexes rocked Thursday's session with gains across the board. The Dow closed up 1.3%, the S&P added 1.1% and the Nasdaq moved higher by 0.7%. Here are Thursday's winners and losers: Winners New York Times Co.
Guidance Analysts are looking for EPS of $1.27 on revenue of $3.79B. The consensus range is $1.20-$1.34 for EPS, and $3.73B-$3.88B for revenue, according to First Call.
Genzyme 's manufacturing issues just won't go away. Four months after the company announced that it had shut down a manufacturing plant because of viral contamination, it's still dealing with the aftermath.
Stocks Slide Lower After Beige Book Unsettles Optimism; EBay and Amgen Report After Hours
U.S. Market Stocks started the day higher after a fresh round of before-market earnings reports, but gave back their gains this afternoon.
Amgen Profit Rises 24% on Cost Cuts; Shares Fall on Delayed Bone Treatment
Amgen Inc., the worlda s largest biotechnology company, said profit increased 24 percent on cost cuts.
Amgen Profit Rises 24% as Core Drug Sales Beat Estimates; Forecast Raised
Amgen Inc., the worlda s largest biotechnology company, said third-quarter profit rose 24 percent as sales of most of its core drugs beat analystsa estimates.
Also on Topix